SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Asks for More Data on AstraZeneca PLC’s (JOBS) Symbicort

April 6, 2009 | 
1 min read
AP -- Drug maker AstraZeneca PLC faces a delay in marketing its asthma treatment Symbicort for young children in the United States after regulators on Monday requested more information about the drug.
Regulatory
AstraZeneca
MORE ON THIS TOPIC
New Opportunity, Businessman Walks Up Stairs Finds Exit Big Door
FDA
FDA’s cell and gene therapy head steps down after 1 year
June 30, 2026
 · 
2 min read
 · 
Michael Gibney
Cancer of the brain as tumor growth diagnosis and symptoms of gliomas meningiomas astrocytomas and oligodendrogliomas as diagnosis of symptoms as a paper sculpture.
Regulatory
FDA hits Praxis with 3-month delay for epilepsy drug verdict
June 30, 2026
 · 
2 min read
 · 
Tristan Manalac
Set of crumpled lumps of different paper isolated on yellow background. Gritty dusty dotted effect, vector elements with jagged edges, old notebook sheets.
Regulatory
Amgen’s Tavneos troubles continue as NEJM retracts pivotal publication
June 30, 2026
 · 
2 min read
 · 
Tristan Manalac
Pointing up with fingers number three. Close up, isolated on white background.
Cancer
Replimune gets early August decision date for twice-rejected melanoma drug
June 26, 2026
 · 
3 min read
 · 
Tristan Manalac